Overview

A Dose-Ranging Clinical Study to Assess the Safety and Efficacy of Subconjunctival Injection of Sirolimus in Patients With Dry Eye in the Controlled Adverse Environmental (CAE) Model

Status:
Completed

Trial end date:
2009-10-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the safety and efficacy of an ocular sirolimus (rapamycin) formulation compared to Placebo on the signs and symptoms of dry eye in the CAE Model.

Phase:

Phase 2

Details

Lead Sponsor:

Santen Inc.

Collaborator:

MacuSight, Inc.

Treatments:

Everolimus
Sirolimus